Th1 versus Th17: Are T cell cytokines relevant in multiple sclerosis?

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 2, 2011, Pages 246-251

  Lovett Racke, Amy E ^a   Yang, Yuhong ^a   Racke, Michael K ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Experimental autoimmune encephalomyelitis; Interferon gamma; Interleukin 17; Multiple sclerosis

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17;

ALLERGIC ENCEPHALOMYELITIS; ARTICLE; BRAIN DAMAGE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MIGRATION; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; EFFECTOR CELL; HUMAN; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TRANSCRIPTION REGULATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-23; MICE; MODELS, IMMUNOLOGICAL; MODELS, NEUROLOGICAL; MULTIPLE SCLEROSIS; STAT4 TRANSCRIPTION FACTOR; T-BOX DOMAIN PROTEINS; TH1 CELLS; TH17 CELLS;

EID: 78650178184     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.05.012     Document Type: Article

References (70)

1. Pettinelli C.B., McFarlin D.E. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt1+2-T lymphocytes. J. Immunol. 1981, 127:1420-1423.
2. McDonald A.H., Swanborg R.H. Antigen-specific inhibition of immune interferon production by suppressor cells of autoimmune encephalomyelitis. J. Immunol. 1988, 140:1132-1138.
3. Ando D.G., Clayton J., Kono D., Urban J.L., Sercarz E.E. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell. Immunol. 1989, 124:132-143.
4. Waldburger K.E., Hastings R.C., Schaub R.G., Goldman S.L., Leonard J.P. Adoptive transfer of experimental allergic encephalomyelitis after in vitro treatment with recombinant murine interleukin-12. Preferential expansion of interferon-gamma-producing cells and increased expression of macrophage-associated inducible nitric oxide synthase as immunomodulatory mechanisms. Am. J. Pathol. 1996, 148:375-382.
5. Yura M., Takahashi I., Serada M., Koshio T., Nakagami K., Yuki Y., Kiyono H. Role of MOG-stimulated Th1 type "light up" (GFP+) CD4+ T cells for the development of experimental autoimmune encephalomyelitis (EAE). J. Autoimmun. 2001, 17:17-25.
6. Lovett-Racke A.E., Rocchini A.E., Choy J., Northrop S.C., Hussain R.Z., Ratts R.B., Sikder D., Racke M.K. Silencing T-bet defines critical role in the differentiation of autoreactive T lymphocytes. Immunity 2004, 21:719-731.
7. Gocke A.R., Cravens P.D., Ben L., Hussain R.Z., Northrop S.C., Racke M.K., Lovett-Racke A.E. T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity. J. Immunol. 2007, 178:1341-1348.
8. Racke M.K., Bonomo A., Scott D.E., Cannella B., Levine A., Raine C.S., Shevach E.M., Rocken M. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med. 1994, 180:1961-1966.
9. Racke M.K., Burnett D., Pak S.H., Albert P.S., Cannella B., Raine C.S., McFarlin D.E., Scott D.E. Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course. J. Immunol. 1995, 154:450-458.
10. Chitnis T., Najafian N., Benou C., Salama A.D., Grusby M.J., Sayegh M.H., Khoury S.J. Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. J. Clin. Invest. 2001, 108:739-747.
11. Bettelli E., Sullivan B., Szabo S.J., Sobel R.A., Glimcher L.H., Kuchroo V.K. Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J. Exp. Med. 2004, 200:79-87.
12. Nath N., Prasad R., Giri S., Singh A.K., Singh I. T-bet is essential for the progression of experimental autoimmune encephalomyelitis. Immunology 2006, 118:384-391.
13. Ferber I.A., Brock S., Taylor-Edwards C., Ridgway W., Dinisco C., Steinman L., Dalton D., Fathman C.G. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J. Immunol. 1996, 156:5-7.
14. Willenborg D.O., Fordham S., Bernard C.C., Cowden W.B., Ramshaw I.A. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J. Immunol. 1996, 157:3223-3227.
15. Lublin F.D., Knobler R.L., Kalman B., Goldhaber M., Marini J., Perrault M., D'Imperio C., Joseph J., Alkan S.S., Korngold R. Monoclonal anti-gamma interferon antibodies enhance experimental allergic encephalomyelitis. Autoimmunity 1993, 16:267-274.
16. Heremans H., Dillen C., Groenen M., Martens E., Billiau A. Chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice: enhancement by monoclonal antibodies against interferon-gamma. Eur. J. Immunol. 1996, 26:2393-2398.
17. Chu C.Q., Wittmer S., Dalton D.K. Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis. J. Exp. Med. 2000, 192:123-128.
18. Becher B., Durell B.G., Noelle R.J. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J. Clin. Invest. 2002, 110:493-497.
19. Gran B., Zhang G.X., Yu S., Li J., Chen X.H., Ventura E.S., Kamoun M., Rostami A. IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J. Immunol. 2002, 169:7104-7110.
20. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., Lucian L., To W., Kwan S., Churakova T., Zurawski S., Wiekowski M., Lira S.A., Gorman D., Kastelein R.A., Sedgwick J.D. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748.
21. Langrish C.L., Chen Y., Blumenschein M., Mattson J., Basham B., Sedgwick J.D., McClanahan T., Kastelein R.A., Cua D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 2005, 201:233-240.
22. Komiyama Y., Nakae S., Matsuki T., Nambu A., Kakuta H.S., Suko K., Iwakura Y. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 2006, 177:566-573.
23. Haak S., Croxford A.L., Dreymborg K., Heppner F.L., Pouly S., Becher B., Waisman A. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J. Clin. Invest. 2009, 119:61-69.
24. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGFbeta in the context of an inflammatory cytokine nilieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189.
25. Bettelli E., Carrier Y., Gao W., Kom T., Strom T.B., Oukka M., Weiner H.L., Kuchroo V.J. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
26. Mangan P.R., Harrington L.E., O'Quinn D.B., Helms W.S., Bullard D.C., Elson C.O., Hatton R.D., Wahl S.M., Schoeb T.R., Weaver C.T. Transforming growth factor-β induces development of the Th17 lineage. Nature 2006, 441:231-234.
27. Yang Y., Weiner J., Liu Y., Smith A.J., Huss D.J., Winger R., Peng H., Cravens P.D., Racke M.K., Lovett-Racke A.E. T-bet is essential for encephalitogenicity of both Th1 and Th17 cells. J. Exp. Med. 2009, 206:1549-1564.
28. Das J., Ren G., Zhang L., Roberts A.I., Zhao X., Bothwell A.L., Van Kaer L., Shi Y., Das G. Transforming growth factor beta is dispensable for the molecular orchestration of Th17 cell differentiation. J. Exp. Med. 2009, 206:2407-2416.
29. Ivanov I.I., McKenzie B.S., Zhou L., Tadokoro C.E., Lepelley A., Lafaille J.J., Cua D.J., Littman D.R. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006, 126:1121-1133.
30. Sun Z., Unutmaz D., Zou Y.R., Sunshine M.J., Pierani A., Brenner-Morton S., Mebius R.E., Littman D.R. Requirement for RORgamma in thymocyte survival and lymphoid organ development. Science 2000, 288:2369-2373.
31. Shinohara M.L., Jansson M., Hwang E.S., Werneck M.B., Glimcher L.H., Cantor H. T-bet-dependent expression of osteopontin contributes to T cell polarization. Proc. Natl. Acad. Sci. USA 2005, 102:17101-17106.
32. Chabas D., Baranzini S.E., Mitchell D., Bernard C.C., Rittling S.R., Denhardt D.T., Sobel R.A., Lock C., Karpuj M., Pedotti R., Heller R., Oksenberg J.R., Steinman L. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001, 294:1731-1735.
33. Jansson M., Panoutsakopoulou V., Baker J., Klein L., Cantor H. Attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice. J. Immunol. 2002, 168:2096-2099.
34. Stromnes I.M., Cerretti L.M., Liggitt D., Harris R.A., Goverman J.M. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat. Med. 2008, 14:337-342.
35. Yednock T.A., Cannon C., Fritz L.C., Sanchez-Madrid F., Steinman L., Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992, 356:63-66.
36. Baron J.L., Madri J.A., Ruddle N.H., Hashim G., Janeway C.A. Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J. Exp. Med. 1993, 177:57-68.
37. Langer-Gould A., Atlas S.W., Green A.J., Bollen A.W., Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J. Med. 2005, 353:375-381.
38. Miller D.H., Khan O.A., Sheremata W.A., Blumhardt L.D., Rice G.P., Libonati M.A., Willmer-Hulme A.J., Dalton C.M., Miszkiel K.A., O'Connor P.W. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J. Med. 2003, 348:15-23. International Natalizumab Multiple Sclerosis Trial Group.
39. Brucklacher-Waldert V., Sturner K., Kolster M., Wolthausen J., Tolosa E. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 2009, 132:3329-3341.
40. Kroenke M.A., Carlson T.J., Andjelkovic A.V., Segal B.M. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J. Exp. Med. 2008, 205:1535-1541.
41. Gyulveszi G., Haak S., Becher B. IL-23-driven encephalo-tropism and Th17 polarization during CNS-inflammation in vivo. Eur. J. Immunol. 2009, 39:1864-1869.
42. Annunziato F., Cosmi L., Santarlasci V., Maggi L., Liotta F., Mazzinghi B., Parente E., Fili L., Ferri S., Frosali F., Giudici F., Romagnani P., Parronchi P., Tonelli F., Maggi E., Romagnani S. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 2007, 204:1849-1861.
43. Liston A., Kohler R.E., Townley S., Haylock-Jacobs S., Comerford I., Caon A.C., Webster J., Harrison J.M., Swann J., Clark-Lewis I., Korner H., McColl S.R. Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response. J. Immunol. 2009, 182:3121-3130.
44. Reboldi A., Coisne C., Baumjohann D., Benvenuto F., Bottinelli D., Lira S., Uccelli A., Lanzavecchia A. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choriod plexus is required for the initiation of EAE. Nat. Immunol. 2009, 10:514-523.
45. Villares R., Cadenas V., Lozano M., Almonacid L., Zaballos A., Martinez C., Varona R. CCR6 regulates EAE pathogenesis by controlling regulatory CD4+ T-cell recruitment to target tissues. Eur. J. Immunol. 2009, 39:1671-1681.
46. Elhofy A., Depaolo R.W., Lira S.A., Lukacs N.W., Karpus W.J. Mice deficient for CCR6 fail to control chronic experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2009, 213:91-99.
47. Olsson T., Zhi W.W., Höjeberg B., Kostulas V., Jiang Y.P., Anderson G., Ekre H.P., Link H. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. J. Clin. Invest. 1990, 86:981-985.
48. Sun J.B., Olsson T., Wang W.Z., Xiao B.G., Kostulas V., Fredrikson S., Ekre H.P., Link H. Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur. J. Immunol. 1991, 21:1461-1468.
49. Voskuhl R.R., Martin R., Bergman C., Dalal M., Ruddle N.H., McFarland H.F. T helper 1 (Th1) functional phenotype of human myelin basic protein-specific T lymphocytes. Autoimmunity 1993, 15:137-143.
50. Pelfrey C.M., Rudick R.A., Cotleur A.C., Lee J.C., Tary-Lehmann M., Lehmann P.V. Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production. J. Immunol. 2000, 165:1641-1651.
51. Allegretta M., Nicklas J.A., Sriram S., Albertini R.J. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 1990, 247:718-721.
52. Lovett-Racke A.E., Trotter J.L., Lauber J., Perrin P.J., June C.H., Racke M.K. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. J. Clin. Invest. 1998, 101:725-730.
53. Burns J., Bartholomew B., Lobo S. Isolation of myelin basic protein-specific T cells predominantly from the memory T-cell compartment in multiple sclerosis. Ann. Neurol. 1999, 45:33-39.
54. Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., Gran B., Eaton J., Antel J., Frank J.A., McFarland H.F., Martin R. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 2000, 6:1167-1175.
55. Matusevicius D., Kivisakk P., He B., Kostulas N., Ozenci V., Fredrikson S., Link H. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult. Scler. 1999, 5:101-104.
56. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., Langer-Gould A., Strober S., Cannella B., Allard J., Klonowski P., Austin A., Lad N., Kaminski N., Galli S.J., Oksenberg J.R., Raine C.S., Heller R., Steinman L. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 2002, 8:500-508.
57. Ishizu T., Osoeawa M., Mei F.J., Kikuchi H., Tanaka M., Takakura Y., Minohara M., Murai H., Mihara F., Taniwaki T., Kira J. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005, 128:988-1002.
58. Kebir H., Ifergan I., Alvarez J.I., Bernard M., Poirier J., Arbour N., Duquette P., Prat A. Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann. Neurol. 2009, 66:390-402.
59. Panitch H.S., Hirsch R.L., Haley A.S., Johnson K.P. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987, 1:893-895.
60. Pouly S., Becher B., Blain M., Antel J.P. Interferon-gamma modulates human oligodendrocyte susceptibility to Fas-mediated apoptosis. J. Neuropathol. Exp. Neurol. 2000, 59:280-286.
61. Vartanian T., Li Y., Zhao M., Stefansson K. Interferon-gamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. Mol. Med. 1995, 1:732-743.
62. Skurkovich S., et al. Randomized study of antibodies to IFN-gamma and TNF-alpha in secondary progressive multiple sclerosis. Mult. Scler. 2001, 7:277-284.
63. Segal B.M., Constantinescu C.S., Raychaudhuri A., Kim L., Fidelus-Gort R., Kasper L.H. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomized, dose-ranging study. Lancet Neurol. 2008, 7:796-804. Ustekinumab MS Investigators.
64. Revel M., Chebath J., Mangelus M., Harroch S., Moviglia G.A. Antagonism of interferon beta on interferon gamma: inhibition of signal transduction in vitro and reduction of serum levels in multiple sclerosis patients. Mult. Scler. 1995, 1(Suppl 1):S5-S11.
65. Durelli L., Conti L., Clerico M., Boselli D., Contessa G., Ripellina P., Ferrero B., Eid P., Novelli F. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann. Neurol. 2009, 65:499-509.
66. Ramgolam V.S., Sha Y., Jin J., Zhang X., Markovic-Plese S. IFN-beta inhibits human Th17 cell differentiation. J. Immunol. 2009, 183:5418-5427.
67. Drulovic J., Savic E., Pekmezovic T., Mesaros S., Stojsavljevic N., Dujmovic-Basuroski I., Kostic J., Vasic V., Mostarica Stojkovic M., Popadic D. Expression of Th1 and Th17 cytokines and transcription factors in multiple sclerosis patients: does baseline T-bet mRNA predict the response to interferon-beta treatment?. J. Neuroimmunol. 2009, 215:90-95.
68. Sutton C., Brereton C., Keogh B., Mills K.M., Lavelle E.C. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med. 2006, 203:1685-1691.
69. Mendel I., Katz A., Kozak N., Ben-Nun A., Revel M. Interleukin-6 functions in autoimmune encephalomyelitis: a study in gene-targeted mice. Eur. J. Immunol. 1998, 28:1727-1737.
70. Okuda Y., Sakoda S., Bernard C.C., Fujimura H., Saeki Y., Kishimoto T., Yanagihara T. IL-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein. Int. Immunol. 1998, 10:703-708.